
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc. is experiencing growth in its Auryon product line, particularly in office-based labs and hospital settings, which positively impacts its average selling price (ASP). The company's gross margin is projected to improve to 52.5%, driven by advancements in manufacturing efficiencies and a favorable shift towards higher-margin Med-Tech revenues. Management's confidence in continued product demand is supported by new customer acquisitions, increased utilization within existing accounts, and successful pricing strategies.
Bears say
AngioDynamics faces significant financial challenges, with management anticipating $4M-$6M in tariff headwinds that will impact overall profitability. Additionally, there is pressure on inventory in the second half of 2026 due to rising raw material costs, which could further strain margins. Despite recent successes in capital sales with NanoKnife disposables exceeding estimates, the broader economic pressures may overshadow these gains, contributing to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares